Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience Inc. has announced the establishment of a Clinical Advisory Board to guide the development of their leading drug candidate, SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD). The board, consisting of preeminent clinical researchers and drug development experts, will play a crucial role as the company prepares for first-in-human clinical trials slated for mid-year. This strategic move signifies Satellos’ transition towards becoming a clinical stage drug development company, with a focus on innovative treatments for muscle diseases.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
